$856 Million is the total value of COMMODORE CAPITAL LP's 30 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 46.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRUS | Buy | MERUS N V | $104,413,938 | -0.9% | 4,428,072 | +10.7% | 12.20% | +3.1% |
| VERA | VERA THERAPEUTICS INCcl a | $74,719,500 | -14.6% | 5,450,000 | 0.0% | 8.73% | -11.1% | |
| XENE | XENON PHARMACEUTICALS INC | $63,025,200 | -11.3% | 1,845,000 | 0.0% | 7.37% | -7.7% | |
| PCVX | Buy | VAXCYTE INC | $56,078,000 | +10.6% | 1,100,000 | +8.4% | 6.56% | +15.1% |
| COGT | COGENT BIOSCIENCES INC | $54,268,754 | -17.7% | 5,566,026 | 0.0% | 6.34% | -14.4% | |
| RYTM | New | RHYTHM PHARMACEUTICALS INC | $47,569,375 | – | 2,075,000 | +100.0% | 5.56% | – |
| AMAM | Buy | AMBRX BIOPHARMA INCsponsored ads | $40,463,394 | -22.6% | 3,518,556 | +10.8% | 4.73% | -19.5% |
| Buy | ENLIVEN THERAPEUTICS INC | $39,638,807 | -17.3% | 2,901,816 | +23.6% | 4.63% | -14.0% | |
| CABA | Buy | CABALETTA BIO INC | $38,441,961 | +25.7% | 2,525,753 | +6.7% | 4.49% | +30.8% |
| IMVT | Buy | IMMUNOVANT INC | $38,390,000 | +124.9% | 1,000,000 | +11.1% | 4.49% | +133.8% |
| Sell | NUVALENT INC | $38,098,925 | -21.4% | 828,778 | -27.9% | 4.45% | -18.3% | |
| VRDN | VIRIDIAN THERAPEUTICS INC | $33,748,000 | -35.5% | 2,200,000 | 0.0% | 3.94% | -32.9% | |
| AKRO | Sell | AKERO THERAPEUTICS INC | $28,577,700 | -63.5% | 565,000 | -66.3% | 3.34% | -62.0% |
| New | SOLENO THERAPEUTICS INC | $26,190,125 | – | 887,500 | +100.0% | 3.06% | – | |
| IDYA | IDEAYA BIOSCIENCES INC | $20,909,500 | +14.8% | 775,000 | 0.0% | 2.44% | +19.4% | |
| CLDX | Buy | CELLDEX THERAPEUTICS INC NEW | $19,447,421 | -9.3% | 706,665 | +11.9% | 2.27% | -5.6% |
| CELC | Buy | CELCUITY INC | $15,484,449 | -2.3% | 1,694,141 | +17.3% | 1.81% | +1.6% |
| ALPN | ALPINE IMMUNE SCIENCES INC | $15,171,250 | +11.4% | 1,325,000 | 0.0% | 1.77% | +15.8% | |
| ADVM | ADVERUM BIOTECHNOLOGIES INC | $15,000,000 | -5.7% | 10,000,000 | 0.0% | 1.75% | -1.9% | |
| CRNX | New | CRINETICS PHARMACEUTICALS IN | $14,870,000 | – | 500,000 | +100.0% | 1.74% | – |
| SNDX | Sell | SYNDAX PHARMACEUTICALS INC | $13,903,031 | -33.4% | 957,509 | -4.0% | 1.62% | -30.7% |
| KURA | KURA ONCOLOGY INC | $12,768,000 | -13.8% | 1,400,000 | 0.0% | 1.49% | -10.4% | |
| Buy | THIRD HARMONIC BIO INC | $10,863,000 | +127.4% | 1,700,000 | +71.1% | 1.27% | +136.5% | |
| DAWN | DAY ONE BIOPHARMACEUTICALS I | $9,075,640 | +2.8% | 739,661 | 0.0% | 1.06% | +7.0% | |
| New | VISTAGEN THERAPEUTICS INC | $8,253,000 | – | 1,575,000 | +100.0% | 0.96% | – | |
| New | RAYZEBIO INC | $6,413,824 | – | 288,911 | +100.0% | 0.75% | – | |
| New | APOGEE THERAPEUTICS INC | $5,325,000 | – | 250,000 | +100.0% | 0.62% | – | |
| MRSN | New | MERSANA THERAPEUTICS INC | $2,850,360 | – | 2,244,378 | +100.0% | 0.33% | – |
| New | AEGLEA BIOTHERAPEUTICS INC | $1,424,969 | – | 116,324 | +100.0% | 0.17% | – | |
| DBVT | DBV TECHNOLOGIES S Asponsored adr | $126,054 | -28.4% | 92,687 | 0.0% | 0.02% | -25.0% | |
| AGLE | Exit | AEGLEA BIOTHERAPEUTICS INC | $0 | – | -2,908,100 | -100.0% | -0.15% | – |
| KALV | Exit | KALVISTA PHARMACEUTICALS INC | $0 | – | -312,553 | -100.0% | -0.32% | – |
| ARWR | Exit | ARROWHEAD PHARMACEUTICALS IN | $0 | – | -610,000 | -100.0% | -2.44% | – |
| CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -2,025,000 | -100.0% | -2.49% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 12 | Q3 2023 | 10.3% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.4% |
| VIRIDIAN THERAPEUTICS INC | 11 | Q3 2023 | 8.9% |
| CYMABAY THERAPEUTICS INC | 11 | Q2 2023 | 5.4% |
| KURA ONCOLOGY INC | 11 | Q3 2023 | 7.1% |
| CELLDEX THERAPEUTICS INC NEW | 11 | Q3 2023 | 3.8% |
| ACLARIS THERAPEUTICS INC | 10 | Q1 2023 | 10.4% |
| CELCUITY INC | 10 | Q3 2023 | 7.3% |
| KALVISTA PHARMACEUTICALS INC | 10 | Q2 2023 | 2.2% |
| MERUS N V | 9 | Q3 2023 | 12.5% |
View COMMODORE CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | April 27, 2023 | 31,181,983 | 8.1% |
| BELLUS Health Inc. | March 30, 2023 | 6,579,359 | 5.2% |
| IMARA Inc. | February 21, 2023 | 2,840,754 | 10.8% |
| Karyopharm Therapeutics Inc. | February 14, 2023 | 1,935,609 | 1.7% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Satsuma Pharmaceuticals, Inc.Sold out | November 16, 2022 | 0 | 0.0% |
| GENOCEA BIOSCIENCES, INC. | February 14, 2022 | 3,079,756 | 5.4% |
View COMMODORE CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| SC 13G | 2024-03-21 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View COMMODORE CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.